Stable Coronary Disease Research Articles

Functional Assessment of Coronary Artery Stenosis from Coronary Angiography and Computed Tomography: Angio-FFR vs. CT-FFR.

This study was designed to compare the diagnostic performance of angio-FFR and CT-FFR for detecting hemodynamically significant coronary stenosis. Angio-FFR and CT-FFR were measured in 110 patients (139 vessels) with stable coronary disease using invasive FFR as the reference standard. On per-patient basis, angio-FFR was highly correlated with FFR (r =0.78, p <0.001), while the correlation was moderate between CT-FFR and FFR (r =0.68, p <0.001). Diagnostic accuracy, sensitivity, and specificity for angio-FFR were 94.6%, 91.4%, and 96.0%, respectively; and those of CT-FFR were 91.8%, 91.4%, and 92%, respectively. Bland-Altman analysis showed that angio-FFR had a larger average difference and a smaller root mean squared deviation than CT-FFR compared with FFR (-0.014±0.056 vs. 0.0003±0.072). Angio-FFR had a slightly higher AUC than that of CT-FFR (0.946 vs. 0.935, p =0.750). Angio-FFR and CT-FFR computed from coronary images could be accurate and efficient computational tools for detecting lesion-specific ischemia of coronary artery stenosis. Angio-FFR and CT-FFR calculated based on the two types of images can both accurately diagnose functional ischemia of coronary stenosis. CT-FFR can act as a gatekeeper to the catheter room, assisting doctors in determining whether patients need to be screened by coronary angiography. Angio-FFR can be used in the catheter room to determine the functional significant stenosis for helping decision-making in revascularization.

Optical coherence tomography factors for adverse events in patients with severe coronary calcification

BackgroundSevere coronary calcification is a factor for worse outcomes after percutaneous coronary intervention. AimsTo identify factors of pre- and post-stent optical coherence tomography (OCT) for device-oriented clinical endpoints (DoCE) in patients with severely calcified lesions requiring drug-eluting stent (DES) implantation. MethodsA total of 237 consecutive patients with stable coronary disease who underwent OCT imaging of severe coronary lesions were included. Lesions with a maximum calcium angle >180°, maximum calcium thickness > 0.5 mm, and calcium length > 5 mm were defined as having severe calcification. ResultsThe prevalence of eruptive calcified nodules (41% vs. 18%, p = 0.002) and medial dissection with calcified flaps (59% vs. 26%, p < 0.001) was significantly higher in patients with DoCE (n = 34) than those without DoCE (n = 203). Multivariate analyses demonstrated that the presence of a medial dissection with calcified flap within the DES-implanted segment was independently associated with a higher incidence of DoCE (odds ratio, 3.367; 95% confidence interval, 1.503–7.543; p = 0.003). The combined presence of eruptive calcified nodules and medial dissection with calcified flaps was associated with a higher incidence of DoCE (p < 0.001) during a median of 756 days after DES implantation. ConclusionsOCT-defined severely calcified lesions with eruptive calcified nodules and medial dissection with calcified flaps were associated with a higher incidence of DoCE after DES implantation.

Clinical Outcome of Revascularization Deferral With Instantaneous Wave-Free Ratio and Fractional Flow Reserve: A 5-Year Follow-Up Substudy From the iFR-SWEDEHEART Trial.

Background Although physiology-based assessment of coronary artery stenosis using instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) are established methods of guiding coronary revascularization, its clinical outcome in long-term deferral needs further evaluation, especially with acute coronary syndrome as a clinical presentation. The aim was to evaluate the long-term clinical outcome of deferral of revascularization based on iFR or FFR. Methods and Results This is a substudy of the iFR-SWEDEHEART (Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina Pectoris or Acute Coronary Syndrome) randomized clinical trial, where patients deferred from revascularization from each study arm were selected. Nine hundred eight patients deferred from coronary revascularization with iFR (n=473) and FFR (n=435) were followed for 5 years. The national quality registry, SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies), was used for patient data collection and clinical follow-up. The end point was major adverse cardiac events and their individual components all-cause death, cardiovascular death, noncardiovascular death, nonfatal myocardial infarction, and unplanned revascularization. No significant difference was found in major adverse cardiac events (iFR 18.6% versus FFR 16.8%; adjusted hazard ratio, 1.08 [95% CI, 0.79-1.48]; P=0.63) or their individual components. Conclusions No differences in clinical outcomes after 5-year follow-up were noted when comparing iFR versus FFR as methods for deferral of coronary revascularization in patients presenting with stable angina pectoris and acute coronary syndrome. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02166736.

High thrombotic risk is associated with higher prevalence of suboptimal stent results in patients with high bleeding risk

Abstract Funding Acknowledgements Type of funding sources: None. Background Shorter duration of dual antiplatelet therapy after drug-eluting stent implantation is required in patients with high bleeding risk (HBR) irrespective of the presence of concomitant high thrombotic risk (HTR). The prevalence of post-stent suboptimal findings in patients with HBR remains unclear. Purpose To clarify the prevalence of post-stent suboptimal findings assessed by optical coherence tomography (OCT) in patients with HBR according to the presence of HTR. Methods A total of 607 consecutive patients with stable coronary disease, who underwent OCT imaging of the culprit lesion were included. HBR was defined based on the Academic Research Consortium for High Bleeding Risk (ARC-HBR). HTR was defined as lesions with diffuse long (≧60 mm), treated with more than three stents, chronic total occlusion or diffuse long lesion (≧32 mm) in patients with diabetes mellitus. Post-stent suboptimal OCT criteria was defined as minimum stent area (MSA) &amp;lt;4.5 mm2, edge dissection and stent malapposition. Results The prevalence of HBR was 55.8%. The prevalence of HTR was significantly higher in patients with HBR than in those without HBR (35.0 vs. 26.6%, p=0.028) (Figure A). Among patients with HBR, the prevalence of post-stent suboptimal OCT criteria was significantly higher in patients with HTR than in those without HTR (86.2 vs. 64.7%, p&amp;lt;0.001), mainly due to the higher prevalence of MSA &amp;lt;4.5 mm2 (Figure B) in patients with HTR. Conclusions HTR was associated with a higher prevalence of post-stent suboptimal findings among patients with HBR. The present results may suggest the importance of optimal stenting in patients with HBR, particularly in those with concomitant HTR.

SerpinG1: A Novel Biomarker Associated With Poor Coronary Collateral in Patients With Stable Coronary Disease and Chronic Total Occlusion.

Background This study aimed to explore predictive biomarkers of coronary collateralization in patients with chronic total occlusion. Methods and Results By using a microarray expression profiling program downloaded from the Gene Expression Omnibus database, weighted gene coexpression network analysis was constructed to analyze the relationship between potential modules and coronary collateralization and screen out the hub genes. Then, the hub gene was identified and validated in an independent cohort of patients (including 299 patients with good arteriogenic responders and 223 patients with poor arteriogenic responders). Weighted gene coexpression network analysis showed that SERPING1 in the light-cyan module was the only gene that was highly correlated with both the gene module and the clinical traits. Serum levels of serpinG1 were significantly higher in patients with bad arteriogenic responders than in patients with good arteriogenic responders (472.53±197.16 versus 314.80±208.92 μg/mL; P<0.001) and were negatively associated with the Rentrop score (Spearman r=-0.50; P<0.001). Receiver operating characteristic curve analysis indicated that the area under the curve was 0.77 (95% CI, 0.72-0.81; P<0.001) for serum serpinG1 in prediction of bad arteriogenic responders. After adjusting for traditional cardiovascular risk factors, serum serpinG1 levels (per SD) remained an independent risk factor for bad arteriogenic responders (odds ratio, 2.20 [95% CI, 1.76-2.74]; P<0.001). Conclusions Our findings illustrate that SERPING1 screened by weighted gene coexpression network analysis was associated with poor collateralization in patients with chronic total occlusion.

Impact of the eicosapentaenoic acid to arachidonic acid ratio on plaque characteristics in statin-treated patients with coronary artery disease

BackgroundA low eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is associated with an increased risk of cardiovascular events in patients with coronary artery disease (CAD). ObjectiveTo clarify the impact of the EPA/AA ratio on the characteristics of non-culprit coronary plaques in statin-treated patients with CAD. MethodsA total of 370 consecutive stable coronary disease patients treated with statins, who underwent percutaneous coronary intervention for the culprit lesion and optical coherence tomography (OCT) imaging of the non-culprit plaque in a culprit vessel were included. The characteristics of non-culprit plaques assessed using OCT were compared between the lower EPA/AA group (EPA/AA <0.4, n = 255) and the higher EPA/AA group (EPA/AA ≥0.4, n = 115). ResultsThe prevalence of lipid-rich plaque (58.8 vs. 41.7%, p = 0.003) and plaque with macrophages (56.5 vs. 31.3%, p <0.001) was significantly higher in the lower EPA/AA group than in the higher EPA/AA group. This association was observed even if the LDL-C level was <100 mg/dL. The prevalence of thin-cap fibroatheroma was significantly higher in patients with lower EPA/AA and higher LDL-C (≥100 mg/dL) than in those with higher EPA/AA and lower LDL-C (<100 mg/dL) (odds ratio: 2.750, 95% confidence interval: 1.182-6.988, p = 0.024). An EPA/AA <0.4 was independently associated with a higher prevalence of lipid-rich plaque, plaque with macrophages, and cholesterol crystals. ConclusionLower EPA/AA ratio was associated with higher prevalence of vulnerable characteristics in non-culprit plaques. The present results suggest the importance of EPA/AA ratio on the secondary prevention of CAD.

STEMI Pakistan; A National Heart Attack Management Program.

Coronary artery disease (CAD) accounts for more than two-thirds of these deaths. It is indicated per the latest information that one in four Pakistani adults over 40 has CAD.&#x0D; The stable coronary disease has a relatively low annual mortality, while acute myocardial infarction (MI) carries a high mortality and morbidity. Though recent advancements in coronary interventions have however revolutionized the management of acute myocardial infarction, resulting in a significant reduction of cardiovascular morbidity and mortality in the developed world but in Pakistan, the majority of ST-elevation myocardial infarction (STEMI) patients still remain sub-optimally managed. Urban areas are relatively better equipped, but this does not necessarily translate into universal access to quality and timely cardiac care. There is not only substantial variation in accessibility and practices amongst cardiac healthcare facilities between rural and urban areas but also amongst major city hospitals. Such variations clearly indicate an urgent need for a nationwide standardized STEMI management program to ensure that everyone with an acute STEMI will have speedy access to quality and standard acute care without being economically burdened.

Abstract 11923: High Sensitivity C-Reactive Protein is Associated With Vulnerable Characteristics in Coronary Plaques in Patients With Stable Coronary Disease

Introduction: Higher level of high sensitivity C-reactive protein (hsCRP) is associated with an increased risk of cardiovascular events in patients with coronary artery disease (CAD). However, the association between hsCRP and the characteristics of coronary plaques in patients with CAD remains to be elucidated. Hypothesis: Higher hsCRP is associated with a higher prevalence of vulnerable characteristics in coronary plaques in patients with CAD. Methods: A total of 793 consecutive patients with stable coronary disease (SCD), who underwent optical coherence tomography (OCT) imaging of coronary plaques were included. The characteristics of culprit or non-culprit plaque assessed by OCT were compared between the higher hsCRP group (hsCRP ≥ 0.2 mg/dL, n=247) and the lower hsCRP group (hsCRP &lt; 0.2 mg/dL, n=546). Results: In culprit plaques, the prevalence of thin-cap fibroatheroma (TCFA) was significantly higher in the higher hsCRP group than in the lower hsCRP group (23.8% vs. 14.9%, p=0.003) (Panel A). In non-culprit plaques, the prevalence of TCFA (28.6 vs. 18.2%, p=0.014) and plaque with marcophages (56.4 vs. 45.1%, p=0.029) was significantly higher in the higher hsCRP group than in the lower hsCRP group (Panel B). Conclusions: Higher level of hsCRP is associated with a higher prevalence of vulnerable characteristics in culprit and non-culprit plaques in patients with CAD. The present results may partly explain the pathogenesis of an increased incidence of ​recurrent cardiovascular events in patients with CAD.

The clinical value and cost-effectiveness of treatments for patients with coronary artery disease

BackgroundThe clinical value and cost-effectiveness of invasive treatments for patients with coronary artery disease is unclear. Invasive treatments such as coronary artery bypass grafting and percutaneous coronary intervention are frequently used as a starting treatment, yet they are much more costly than optimal medical therapy. While patients may transition into other treatments over time, the choices of starting treatments are likely important determinants of costs and health outcomes. The aim is to predict by how much costs and health outcomes will change from a decision to use different starting treatments for patients with coronary artery disease in an Asian setting.MethodsA cost-effectiveness study using a Markov model informed by data from Singapore General Hospital was done. All patients with initial presentations of stable coronary disease and no acute coronary syndromes who received medical treatments and interventional therapies were included. We compare existing practice, where the starting treatment can be medical therapy or stent percutaneous coronary interventions or coronary artery bypass grafting, with alternate starting treatment strategies.ResultsWhen compared to ‘existing practice’ a policy of starting 14% of patients with coronary artery bypass grafting and 86% with optimal medical therapy showed savings of $1,743 per patient and 0.23 additional quality adjusted life years. A change to policy nationwide would save $10 million and generate 1,380 quality adjusted life years.ConclusionsIncreasing coronary artery bypass grafting and use of medical therapy in the setting of coronary artery disease is likely to saves costs and improve health outcomes. A definitive study to address the question we investigate would be very difficult to undertake and so using existing data to model the expected outcomes is a useful tool. There are likely to be large and complex barriers to the implementation of any policy change based on the findings of this study.

Effect of Percutaneous Coronary Intervention (PCI) on Quality of Life in Patients with Stable Coronary Disease

Background: The most popular form of treatment for coronary disease is percutaneous coronary intervention (PCI). Along with recurrence rates and mortality, quality of life (QoL) is a crucial PCI outcome indicator. Purpose: The purpose of this research was to look at the variables affecting individuals with coronary disease who had undergone PCI's quality of life. The cardiac center of the hospital provided a convenient sampling for this descriptive, cross-sectional research. On a population of 630 patients who had coronary disease, this research was carried out utilizing a standardized questionnaire and individual medical data. Information on general, medical, and psychological traits was gathered using the questionnaire. Descriptive statistics, the independent t-test, one-way variance analysis and Scheffé test were all used to analyze the data. The significant variables in univariate analysis were combined with the key parameters found in a multiple linear regression to identify the factors that strongly affected QoL. Results: We discovered that age, subjective economic status, being the primary caregiver, time since the first PCI, anxiety, and depression all significantly influenced QoL. The Age, primary caregivers and marital status were the strongly significant variables that were proven to have an impact on QoL in patients who had gone through PCI. The period since the initial PCI was among the main clinical factors that were proven to have an impact on QoL. Depression and anxiety were among the important psychosocial traits that were found to have an impact on quality of life. The study's PCI patients' primary caregivers were shown to have the biggest influence on their quality of life. Conclusions: Patients' post-PCI psychological and physical symptoms must be frequently evaluated in order to improve QoL in those who had underwent PCI. In addition, patients with significant functional impairments and those getting family care need intervention measures that aim at enhancing quality of life.

Antithrombotic and proton pump inhibitor co-therapy in patients with atrial fibrillation and stable coronary disease: a post hoc analysis of the AFIRE trial

Abstract Background Among patients with atrial fibrillation (AF) and stable coronary artery disease, bleeding events increased the cardiovascular events and mortality. We aimed to evaluate the effect of proton pump inhibitor (PPI) on the risk of bleeding events in these patients. Methods In the AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease), patients with non-valvular AF and coronary artery disease were recruited and randomized to receive the rivaroxaban monotherapy or combination therapy with rivaroxaban plus antiplatelet drug. The present sub-analysis evaluated the risks of any bleeding events. Results Among 2,225 patients, 1,357 (61.3%) were receiving a PPI at baseline. During follow-up, 384 bleeding events were occurred, and incidence of bleeding events were significantly lower in patients with PPI compared with those without PPI (p=0.03). Among combination therapy with rivaroxaban plus antiplatelet, effect of PPI for cumulative incidence of bleeding events were significantly different between groups (p=0.01), however, these differences were not shown among rivaroxaban monotherapy patients (p=0.50, Figure 1). Multivariate Cox hazard analysis showed that PPI use had significantly lower risk of bleeding events (hazard risk 0.79, 95% confidence interval 0.64–0.97, p=0.03). In addition to PPI, male, heart failure and combination therapy with rivaroxaban plus antiplatelet drug were independent predictors of bleeding events. Conclusions PPI use was significantly associated with lower risk of bleeding events among patients with AF and stable coronary artery disease. Especially, for patients at high bleeding risk, such as receiving both anticoagulant and antiplatelet drugs, PPI is useful to reduce bleeding events. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): The Japan Cardiovascular Foundation through a contract with Bayer Yakuhin.

Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina – a prospective Norwegian cohort

Abstract Background and methods Recent guidelines have included glycated haemoglobin (HbA1c) ≥48 mmol/L as a diagnostic criterion for diabetes mellitus (DM) in addition to plasma glucose (PG) concentrations, mainly based on the relationship between hyperglycemia and microvascular disease [1]. However, increased HbA1c may stem not only from hyperglycemia, and the risk association between HbA1c and long-term survival in patients with stable coronary heart disease and HbA1c ≥48 mmol/L but no previous DM according to PG is uncertain. We explored the relationship between HbA1c and survival among patients with and without DM who were evaluated for stable angina in the period 2000–2004. Endpoints were obtained from the Norwegian Cause of Death Registry. Results In total, 4164 patients were evaluated by cardiac cathetherization, of whom 576 patients (13.8%) had DM (median HbA1c 55 mmol/L) according to self-report and/or baseline PG concentrations. Of the remaining 3588 patients 1026 had HbA1c ≥48 mmol/L; however, HbA1c did not correlate with the HOMA2 insulin resistance index or fasting PG in these patients. During median (25–75 percentile) follow-up time of 14.0 (12.1–15.4) years a total of 1328 patients (31.9%) died, of whom 582 from cardiovascular causes. In patients with DM according to PG, HbA1c trended towards positive associations with all-cause and CVD mortality when adjusted for age and gender (HRs (95% CIs) 1.13 (0.99–1.28) and 1.16 (0.98–1.39) per 1SD, respectively). However, HbA1c was not associated with survival in either the group of patients without DM and HbA1c &amp;lt;48 mmol/L (median HbA1c 38 mmol/L) (HRs (95% CIs) 0.99 (0.92–1.06) and 0.96 (0.86–1.08) for all-cause and CVD mortality, respectively) or patients without DM but having HbA1c ≥48 mmol/L (median HbA1c 53 mmol/L) (HRs (95% CIs) 0.99 (0.88–1.12) and 1.04 (0.88–1.22)). Conclusion In patients evaluated for stable angina pectoris about two decades ago, almost a third of patients with no history of DM according to PG still had HbA1c concentrations indicating DM according to current guidelines. Including these patients in the DM category yielded similar percentages of patients with DM as observed in recent populations with stable coronary disease [2]. However, as opposed to what we observed in patients with DM, HbA1c did not show any association with very long-term survival among patients without DM. Our findings therefore question the use of HbA1c in the diagnosis of DM, especially in terms of risk assessment for longevity among patients with chronic coronary syndrome. Funding Acknowledgement Type of funding sources: None.

Higher triglyceride level is associated with the higher prevalence of layered plaque in nonculprit coronary plaques

Abstract Background The impact of the high triglyceride (TG) level on the characteristics of coronary plaque in nonculprit lesion remains to be elucidated. Purpose To clarify the association between the TG level and the characteristics of nonculprit coronary plaque in patients with stable coronary disease using optical coherence tomography (OCT). Methods A total of 531 consecutive patients who underwent OCT imaging of the nonculprit lesion were included. Patients were classified into either the higher TG group (non-fasting TG ≥150 mg/dL, n=197) or the lower TG group (non-fasting TG &amp;lt;150 mg/dL, n=334). The morphologies of nonculprit plaque assessed by OCT were compared between the two groups. Results The median (interquartile range) of TG in the two groups was 193.0 (168.0–244.0) mg/dL and 95.0 (75.0–120.0) mg/dL, respectively. The prevalence of layered plaque was significantly higher in the higher TG group than the lower TG group (40.1 vs. 27.5%, p=0.004), whereas the prevalence of other plaque components was comparable between the two groups (Figure 1). The prevalence of layered plaque was significantly higher in the higher TG group than in the lower TG group among patients with diabetes mellitus (DM) (44.2 vs. 28.7%, p=0.037) although it was comparable between the two groups among patients without DM (Figure 2). Conclusion A higher TG level was associated with a higher prevalence of layered plaque in nonculprit plaques in patients with stable coronary disease, particularly in patients with DM. The present results may partly explain the impact of TG on the progression of coronary plaque and the increased incidence of recurrent events in patients with coronary artery disease. Funding Acknowledgement Type of funding sources: None.

Long-term clinical outcome in patients with isolated chronic total occlusion treated percutaneously or pharmacologically

Abstract Purpose Chronic Total Coronary Occlusion (CTO) is defined as the total obstruction of coronary blood flow for at least 3 months duration. The aim of this study was to compare the long-term clinical outcome in patients with stable angina (CCS I-III) and isolated CTO treated with successful percutaneous coronary intervention (PCI) or conservative management (a priori pharmacologically or after failed PCI) and to detect potential risk factors of unsuccessful PCI. Methods The inclusion criteria were: isolated CTO of one CA, previously confirmed viability of myocardium in the area of occluded CA, stable coronary disease, absence of significant valve disease resulting in predicted survival below 1 year. Choice of management was based on individualized risk/benefit analysis encompassing ischemia assessment and angiographic considerations. Clinical follow-up of 24 months duration was conducted with regard to occurrence of major adverse cardiac events (MACE) including death, acute myocardial infarction (MI), need for repeat revascularization (surgical or PCI), major bleeding and hospitalization for angina. Results The study group consisted of 119 pts with isolated CTO (88 males, mean age 60.7±9.6 years)– 75 (63%) in the right CA, 28 (23,5%) in the left anterior descending CA, 16 (13,5%) in the circumflex CA. The history of MI was revealed in 37 pts in medically treated group, 10 pts in PCI group and 7 pts after failed PCI. Successful PCI was performed in 39 (33%) pts while 80 (67%) pts were treated pharmacologically (16 after failed PCI). Over a mean 24-months follow-up there were 58 MACE in all groups, including: 2 cardiac deaths (1 in medically treated group and 1 in PCI group), hospitalization due to angina in 17 pts (10 in medically treated group, 6 in PCI group, 1 after failed PCI), 4 repeated revascularizations (1 in PCI group, 3 after failed PCI), 33 pts developed unstable angina (25 medically treated, 6 in PCI group, 2 after failed PCI), major bleeding occurred in 2 pts in medically treated group. The risk of MACE was lower in pts after successful PCI comparing both with patients treated medically as well as those with failed PCI (p=0.05 for both). Univariate analysis showed that left ventricular endsystolic (p=0.001) and enddiastolic diameter (p=0.01), left ventricular ejection fraction (p=0.03), higher NYHA class (p=0.002) and duration of angina (p=0.05) were significant predictors of MACE. Multivariate analysis identified two independent predictors of MACE: absence of effective PCI (as an intention-to-treat and per protocol) (OR 3.6, 95% CI 1.6–8.3) and larger left ventricular systolic diameter (OR=1.16, 95% CI 1.04–1.29). The independent negative predictors of procedural success were severity of calcification (p=0.001) and length of occlusion (p=0.02). Conclusions Successful PCI of CTO leads to a significant reduction in MACE in 24 months follow-up. Failed PCI is predicted by the occlusion length and extent of calcification. Funding Acknowledgement Type of funding sources: None.

Microarray analysis reveals the potential molecular mechanism of Lp299v in stable coronary atherosclerotic disease

A growing body of evidence has confirmed that inflammatory mechanisms are involved in the formation and treatment of coronary atherosclerotic disease (CAD). An increase in circulatory levels of inflammatory cytokines has been found in patients with CAD, while the molecular mechanisms of inflammation still remain elusive. This study was designed to identify differentially expressed genes (DEGs), and to explore the molecular mechanism and hub genes that are involved in the effects of Lactobacillus plantarum 299v (Lp299v) supplementation. Microarray dataset (GSE156357) was downloaded from the Gene Expression Omnibus (GEO) database. The DEGs were identified by the R software. Then, the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses and construction of protein–protein interaction (PPI) network were performed by DAVID, STRING, and Cytoscape software. In daily alcohol user (DAU) group, 7,541 DEGs were identified, including 206 up-regulated and 7,335 down-regulated DEGs. In non-daily alcohol user (non-DAU) group, 2,799 DEGs were identified (2,491 up-regulated and 308 down-regulated DEGs). The GO enrichment analysis revealed that miosis was up-regulated and immune response was down-regulated. The KEGG enrichment analysis showed that Lp299v supplementation reduced the levels of chemotactic cytokines, and weakened immune response. Proteins of G protein-coupled receptor, inflammatory response, regulation of cell proliferation and apoptosis-related proteins were found in the PPI network. The hub genes were associated with G protein-coupled receptor, inflammatory response, and cell proliferation and apoptosis. The weighted gene co-expression network analysis (WGCNA) enriched the DEGs in 4 modules. This study indicated the expressions of chemokine receptors and regulation of immune response in the Lp299v supplementation. Meanwhile, it was supposed that chemokine receptors may have a cellular effect.

Prognostic Role of Cardiac Troponin I after Percutaneous Coronary Intervention in Stable Coronary Disease

Cardiac troponin I is a highly sensitive and specific marker of myocardial necrosis. In addition to the strong diagnostic role of cardiac troponin I its prognostic value has become increasingly well established for patients presenting with acute coronary syndrome. However, there have been conflicting reports on the value of troponin in the setting of PCI is stable and unstable coronary disease.&#x0D; Objective: To assess the role of cardiac troponin I in predicting outcome after PCI.&#x0D; Methods and results: CTnl was measured immediately before and at 8 hrs and at chest pain after PCI in 80 consecutive patients with stable coronary artery disease. Twenty of them with post procedural CTnl level 50.4 ng/ml were excluded because of the inability to do repeat estimation of CTnl at chest pain. Among the rest sixty patients, thirty had post procedural troponin &lt;0.4 ng/ml were considered as group I and thirty had post procedural rise of CTnI &gt;0.4 ng/ml were considered as group II. CTnl level, 0.4 ng/ml was consider as cut off value for grouping patients was based on ACC/ AHA/ ISCAI 2005 guide line definition of peri procedural myocardial infarction. The study end point was the following adverse cardiac events-recurrent angina, cardiogenic shock, significant arrythmias, congestive heart failure, Q wave MI, repeat PCI/ CABG, death during hospital stay and at 30 days follow up. In this study base line parameters like age, sex, BMI, risk factors, anginal class, base line ECG and LVEF showed no statistically significant difference between the two groups. Angiographic parameters such as types of lesion and procedural complications shows statistically significant difference between two groups. In-hospital adverse cardiac events after the procedure was significantly higher in group II than group 1 (P&lt;0.01). The mean duration of post procedural hospital stay was also significantly higher in group II than group 1 (P&lt;0.01). At 30 days follow up there has no incremental risk of adverse cardiac events.&#x0D; Conclusion: CTnl rise at peri procedural myocardial infarction level was observed in 37.5% of this study patient. This level of CTnl was significantly predictive of an increased risk of adverse cardiac events at hospital follow up.&#x0D; Central Medical College Journal Vol 5 No 2 Jul 2021 PP 106-115

Apolipoprotein C3 and necrotic core volume are correlated but also associated with future cardiovascular events

We aimed to clarify the relationship between apolipoprotein C3 (apo-C3) and the vascular composition of lesion plaque in stable coronary disease (SCD) before percutaneous coronary intervention (PCI), and to investigate major adverse cardiovascular events (MACEs) within 4 years. Data of 98 consecutive patients with SCD who underwent PCI between November 1, 2012, and March 10, 2015, were analyzed. Laboratory and virtual histology-intravascular ultrasound (VH-IVUS) examinations of culprit lesions were conducted before PCI. Patients were divided according to median apo-C3 into low apo-C3 (≤ 8.5 mg/dL) and high apo-C3 (> 8.5 mg/dL) groups. VH-IVUS data indicated that the percentage of necrotic core volume (%NC) was significantly higher in the high apo-C3 group than in the low apo-C3 group. Moreover, the %NC significantly correlated with the apo-C3 level (R = 0.2109, P = 0.037). Kaplan–Meier curve analysis revealed that freedom from MACEs exhibited a greater decrease in the high apo-C3 group than in the low apo-C3 group, and in the high %NC group than in the low %NC group. Multivariate Cox hazards analysis showed that the %NC and high apo-C3 were independent predictors of 4 year MACEs. Apo-C3 may be a useful marker of future MACEs in patients with SCD after PCI and contribute to %NC growth.

Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.

ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarction (MI) compared with a conservative treatment strategy in patients with advanced chronic kidney disease, stable coronary disease, and moderate or severe myocardial ischemia. The cumulative frequency of different MI type after randomization and subsequent prognosis have not been reported. MI classification was based on the Third Universal Definition for MI. For procedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas the secondary MI definition used cTn (cardiac troponin); both definitions included elevated biomarker-only events with higher thresholds than nonprocedural MIs. The cumulative frequency of MI type according to treatment strategy was determined. The association of MI with subsequent all-cause death and new dialysis initiation was assessed by treating MI as a time-dependent covariate. The 3-year incidence of type 1 or 2 MI with the primary MI definition was 11.2% in invasive treatment strategy and 13.6% in conservative treatment strategy (hazard ratio [HR], 0.66 [95% CI, 0.42-1.02]). Procedural MIs were more frequent in invasive treatment strategy and accounted for 9.8% and 28.3% of all MIs with the primary and secondary MI definitions, respectively. Patients had an increased risk of all-cause death after type 1 MI (adjusted HR, 4.35 [95% CI, 2.73-6.93]) and after procedural MI with the primary (adjusted HR, 2.75 [95% CI, 0.99-7.60]) and secondary MI definitions (adjusted HR, 2.91 [95% CI, 1.73-4.88]). Dialysis initiation was increased after a type 1 MI (HR, 6.45 [95% CI, 2.59-16.08]) compared with patients without an MI. In ISCHEMIA-CKD, the invasive treatment strategy had higher rates of procedural MIs, particularly with the secondary MI definition, and lower rates of type 1 and 2 MIs. Procedural MIs, type 1 MIs, and type 2 MIs were associated with increased risk of subsequent death. Type 1 MI increased the risk of dialysis initiation. URL: https://www. gov; Unique identifier: NCT01985360.

Dynamics of the quality of life after CABG in patients with stable ischemic coronary disease

Background and Aims : To evaluate QOL, LV diastolic function parameters and brain natriuretic peptide (BNP) in patients with CAD and preserved or mid-range LVEF before and 6 months after CABG.Methods: The cross-sectional single-center retrospective study included data from clinical and instrumental examination of 71 patients with CAD and preserved or mid-range systolic function (LVEF 40 >%), consecutively selected for CABG. Among them, there were 60 men and 11 women,middle age (64±4) years. 11 (17%) patients had signs of stable angina II FC, 44 (69%) had III FC, 9 (14%) had IV FC. We analyzed FC of angina, QOL parameters by using SF-36, SAQ, MLHFQ, the echocardiographic parameters and the BNP level before and 6 months after CABGResults: Six months after CABG a significant improvement of QOL was registered by questionnaires MLHFQ, SF-36 and SAQ, compared to base[1]line(p <0,001). The angina symptoms significantly decreased: there were no angina attacks in 59% patients, and I-II FC were observed in 39% patients (p <0,001). Six months after surgery, there was a significant improvement in LV diastolic function, namely reduction of DT from median 262 to 250 ms (p <0,001), IVRT from 118 to 112 ms (p = 0,021), and increase of E/A from 0,82 to 0,92 ( p = 0,043). The BNP level decreased from 115,4 to 52,4 pg/ml (p <0,001).Conclusions: Reducing angina pectoris and improving parameters of QOL 6 months after CABG is associated with positive changes of LV diastolic function parameters and decrease of BNР Background and Aims : To evaluate QOL, LV diastolic function parameters and brain natriuretic peptide (BNP) in patients with CAD and preserved or mid-range LVEF before and 6 months after CABG. Methods: The cross-sectional single-center retrospective study included data from clinical and instrumental examination of 71 patients with CAD and preserved or mid-range systolic function (LVEF 40 >%), consecutively selected for CABG. Among them, there were 60 men and 11 women,middle age (64±4) years. 11 (17%) patients had signs of stable angina II FC, 44 (69%) had III FC, 9 (14%) had IV FC. We analyzed FC of angina, QOL parameters by using SF-36, SAQ, MLHFQ, the echocardiographic parameters and the BNP level before and 6 months after CABG Results: Six months after CABG a significant improvement of QOL was registered by questionnaires MLHFQ, SF-36 and SAQ, compared to base[1]line(p <0,001). The angina symptoms significantly decreased: there were no angina attacks in 59% patients, and I-II FC were observed in 39% patients (p <0,001). Six months after surgery, there was a significant improvement in LV diastolic function, namely reduction of DT from median 262 to 250 ms (p <0,001), IVRT from 118 to 112 ms (p = 0,021), and increase of E/A from 0,82 to 0,92 ( p = 0,043). The BNP level decreased from 115,4 to 52,4 pg/ml (p <0,001). Conclusions: Reducing angina pectoris and improving parameters of QOL 6 months after CABG is associated with positive changes of LV diastolic function parameters and decrease of BNР

Use and Cost of Low-Value Health Services Delivered or Paid for by the Veterans Health Administration

Within the Veterans Health Administration (VA), the use and cost of low-value services delivered by VA facilities or increasingly by VA Community Care (VACC) programs have not been comprehensively quantified. To quantify veterans' overall use and cost of low-value services, including VA-delivered care and VA-purchased community care. This cross-sectional study assessed a national population of VA-enrolled veterans. Data on enrollment, sociodemographic characteristics, comorbidities, and health care services delivered by VA facilities or paid for by the VA through VACC programs were compiled for fiscal year 2018 from the VA Corporate Data Warehouse. Data analysis was conducted from April 2020 to January 2022. VA administrative data were applied using an established low-value service metric to quantify the use of 29 potentially low-value tests and procedures delivered in VA facilities and by VACC programs across 6 domains: cancer screening, diagnostic and preventive testing, preoperative testing, imaging, cardiovascular testing and procedures, and other procedures. Sensitive and specific criteria were used to determine the low-value service counts per 100 veterans overall, by domain, and by individual service; count and percentage of each low-value service delivered by each setting; and estimated cost of each service. Among 5.2 million enrolled veterans, the mean (SD) age was 62.5 (16.0) years, 91.7% were male, 68.0% were non-Hispanic White, and 32.3% received any service through VACC. By specific criteria, 19.6 low-value services per 100 veterans were delivered in VA facilities or by VACC programs, involving 13.6% of veterans at a total cost of $205.8 million. Overall, the most frequently delivered low-value service was prostate-specific antigen testing for men aged 75 years or older (5.9 per 100 veterans); this was also the service with the greatest proportion delivered by VA facilities (98.9%). The costliest low-value services were spinal injections for low back pain ($43.9 million; 21.4% of low-value care spending) and percutaneous coronary intervention for stable coronary disease ($36.8 million; 17.9% of spending). This cross-sectional study found that among veterans enrolled in the VA, more than 1 in 10 have received a low-value service from VA facilities or VACC programs, with approximately $200 million in associated costs. Such information on the use and costs of low-value services are essential to guide the VA's efforts to reduce delivery and spending on such care.